Topical delivery of MEK inhibitor binimetinib prevents the development of cutaneous neurofibromas in Neurofibromatosis type 1 mutant mice.
F Coulpier, P Pulh, L Oubrou, J Naudet… - … Research: the Journal …, 2023 - europepmc.org
Cutaneous neurofibromas (cNFs) are a hallmark of patients with the neurofibromatosis type
1 (NF1) genetic disorder. These benign nerve sheath tumors, which can amount to
thousands, develop from puberty onward, often cause pain and are considered by patients
to be the primary burden of the disease. Mutations of NF1, encoding a negative regulator of
the RAS signaling pathway, in the Schwann cell (SCs) lineage are considered to be at the
origin of cNFs. The mechanisms governing cNFs development are poorly understood, and …
1 (NF1) genetic disorder. These benign nerve sheath tumors, which can amount to
thousands, develop from puberty onward, often cause pain and are considered by patients
to be the primary burden of the disease. Mutations of NF1, encoding a negative regulator of
the RAS signaling pathway, in the Schwann cell (SCs) lineage are considered to be at the
origin of cNFs. The mechanisms governing cNFs development are poorly understood, and …
Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant …
F Coulpier, P Pulh, L Oubrou, J Naudet, L Fertitta… - Translational …, 2023 - Elsevier
Cutaneous neurofibromas (cNFs) are a hallmark of patients with the neurofibromatosis type
1 (NF1) genetic disorder. These benign nerve sheath tumors, which can amount to
thousands, develop from puberty onward, often cause pain and are considered by patients
to be the primary burden of the disease. Mutations of NF1, encoding a negative regulator of
the RAS signaling pathway, in the Schwann cell (SCs) lineage are considered to be at the
origin of cNFs. The mechanisms governing cNFs development are poorly understood, and …
1 (NF1) genetic disorder. These benign nerve sheath tumors, which can amount to
thousands, develop from puberty onward, often cause pain and are considered by patients
to be the primary burden of the disease. Mutations of NF1, encoding a negative regulator of
the RAS signaling pathway, in the Schwann cell (SCs) lineage are considered to be at the
origin of cNFs. The mechanisms governing cNFs development are poorly understood, and …
